18 DIABETIC PATIENTS IMPLANTED WITH VERIMED RFID MICROCHIP AT ATLANTA DIABETES
EXPO
March 12, 2007
-- VeriChip Corporation (Nasdaq: CHIP), a provider of RFID systems
for healthcare and patient-related needs, announced today it added 18 diabetic patients to its VeriMed Patient Identification
System at an Atlanta Diabetes EXPO sponsored by the American Diabetes Association (ADA).
At the Diabetes EXPO, physicians implanted VeriMed RFID microchips
in conference attendees who signed up for the voluntary procedure. The VeriMed Patient Identification System, which utilizes
an implantable RFID microchip in combination with a handheld RFID scanner and a secure patient database, provides immediate
access to important health information for patients who arrive at an emergency department unable to communicate.
Scott R. Silverman, Chairman and CEO of VeriChip, commented, "We
believe the VeriMed Patient Identification System is an essential health care solution for at-risk patients, including diabetics,
who tend to present with various co-morbidities and medications, and are more frequently admitted to emergency departments.
Since the inception of the VeriMed System, we always knew that the diabetic community was in need of a way to communicate
their medical information better and more frequently. We will continue to focus on diabetics and to enhance our relationship
further with the American Diabetes Association. The Atlanta Diabetes EXPO provides us direct access so we can continue to
educate an important target audience."
The Diabetes EXPO is a patient-driven tradeshow, including professional
speakers and a variety of ADA program/event information, where
exhibitors from pharmaceutical and medical device companies display beneficial products for diabetics. The Diabetes EXPO began
in 1995 in Phoenix, Arizona, and has grown to 18, metro, major
and mid-size cities around the U.S. The
next event will be held in Boston on March 17, 2007. of Section
27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the
Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to
change at any time, and the Company's actual results could differ materially from expected results. The Company undertakes
no obligation to update forward-looking statements to reflect subsequently occurring events or circumstances.
